Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894322 | 1.00 | NPC1 (0.40) | NPC1RAB9AKMT2AEPHX2POLB | |
| SCHEMBL1521947 | 0.90 | RAB9A (0.41) | NPC1RAB9AKMT2AEPHX2POLB | |
| SCHEMBL1522057 | 0.88 | NPC1 (0.39) | NPC1RAB9AKMT2AEPHX2POLB | |
| SCHEMBL1521987 | 0.88 | FGFR1 (0.43) | NPC1RAB9AKMT2AEPHX2POLB | |
| SCHEMBL4566422 | 0.86 | FGFR2 (0.39) | EPHX2PARP1FGFR1FGFR2FGFR3 | |
| SCHEMBL1521676 | 0.86 | PARP1 (0.38) | NPC1RAB9AKMT2AEPHX2POLB | |
| SCHEMBL1522021 | 0.83 | BRAF (0.53) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL1522016 | 0.76 | KDR (0.50) | FGFR1FGFR2FGFR3FGFR4BRAF | |
| SCHEMBL1521844 | 0.76 | FGFR1 (0.42) | NPC1RAB9AKMT2AEPHX2POLB | |
| SCHEMBL4563487 | 0.76 | PARP1 (0.40) | NPC1RAB9AKMT2AEPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021084266-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INUCED KINASE SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | claimed |
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | claimed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | claimed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | claimed |
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-30 | — | — | US | disclosed |
| US-20230014742-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| WO-2021084266-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INUCED KINASE SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | NPC1 4287/4885RAB9A 1244/4885KMT2A 1762/4885 |
| US-20230014742-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | SIK2, SIK1, SIK3 | NPC1 4022/4885RAB9A 2102/4885KMT2A 1107/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | NPC1 4287/4885RAB9A 1244/4885KMT2A 1762/4885 |
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | SIK2, SIK1, SIK3 | NPC1 1801/4885RAB9A 2439/4885KMT2A 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.